TR200402275T2 - Nörotik düzensizliklerin tedavisi - Google Patents

Nörotik düzensizliklerin tedavisi

Info

Publication number
TR200402275T2
TR200402275T2 TR2004/02275T TR200402275T TR200402275T2 TR 200402275 T2 TR200402275 T2 TR 200402275T2 TR 2004/02275 T TR2004/02275 T TR 2004/02275T TR 200402275 T TR200402275 T TR 200402275T TR 200402275 T2 TR200402275 T2 TR 200402275T2
Authority
TR
Turkey
Prior art keywords
treatment
neurotic disorders
irregularity
escitalopramine
citalopramine
Prior art date
Application number
TR2004/02275T
Other languages
English (en)
Turkish (tr)
Inventor
Sanchez Connie
Hogg Sandra
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8099796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR200402275(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of TR200402275T2 publication Critical patent/TR200402275T2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TR2004/02275T 1999-07-08 2000-07-07 Nörotik düzensizliklerin tedavisi TR200402275T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA199900991 1999-07-08

Publications (1)

Publication Number Publication Date
TR200402275T2 true TR200402275T2 (tr) 2005-03-21

Family

ID=8099796

Family Applications (4)

Application Number Title Priority Date Filing Date
TR2004/02275T TR200402275T2 (tr) 1999-07-08 2000-07-07 Nörotik düzensizliklerin tedavisi
TR2002/00014T TR200200014T2 (tr) 1999-07-08 2000-07-07 Nörotik düzensizliklerin tedavisi.
TR2004/02276T TR200402276T2 (tr) 1999-07-08 2000-07-07 Nörotik düzensizliklerin tedavisi
TR2004/02277T TR200402277T2 (tr) 1999-07-08 2000-07-07 Nörotik düzensizliklerin tedavisi

Family Applications After (3)

Application Number Title Priority Date Filing Date
TR2002/00014T TR200200014T2 (tr) 1999-07-08 2000-07-07 Nörotik düzensizliklerin tedavisi.
TR2004/02276T TR200402276T2 (tr) 1999-07-08 2000-07-07 Nörotik düzensizliklerin tedavisi
TR2004/02277T TR200402277T2 (tr) 1999-07-08 2000-07-07 Nörotik düzensizliklerin tedavisi

Country Status (38)

Country Link
US (6) US7271194B2 (https=)
EP (4) EP1440691A3 (https=)
JP (1) JP4773011B2 (https=)
KR (1) KR100604176B1 (https=)
CN (1) CN1198610C (https=)
AR (1) AR021155A1 (https=)
AT (1) ATE339955T1 (https=)
AU (6) AU782514B2 (https=)
BG (4) BG106279A (https=)
BR (1) BR0011578A (https=)
CA (4) CA2687396A1 (https=)
CL (3) CL2008003941A1 (https=)
CO (1) CO5190674A1 (https=)
CY (1) CY1105806T1 (https=)
CZ (1) CZ200270A3 (https=)
DE (1) DE60030861T2 (https=)
DK (1) DK1200081T3 (https=)
EA (1) EA006555B1 (https=)
ES (1) ES2272298T3 (https=)
HK (1) HK1048069B (https=)
HR (1) HRP20010820A2 (https=)
HU (1) HUP0201791A3 (https=)
IL (5) IL146131A0 (https=)
IS (1) IS6137A (https=)
ME (2) MEP2508A (https=)
MX (1) MXPA01011626A (https=)
MY (1) MY143278A (https=)
NO (4) NO329021B1 (https=)
PL (1) PL352030A1 (https=)
PT (1) PT1200081E (https=)
SI (1) SI1200081T1 (https=)
SK (1) SK82002A3 (https=)
TR (4) TR200402275T2 (https=)
TW (1) TWI232101B (https=)
UA (1) UA77645C2 (https=)
WO (1) WO2001003694A1 (https=)
YU (1) YU78701A (https=)
ZA (1) ZA200108856B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
GB0005477D0 (en) 2000-03-07 2000-04-26 Resolution Chemicals Limited Process for the preparation of citalopram
WO2002008216A1 (en) 2000-07-21 2002-01-31 H. Lundbeck A/S Novel compounds and their use as glycine transport inhibitors
EA200301195A1 (ru) * 2001-05-01 2004-04-29 Х. Лундбекк А/С Применение энантиомерно чистого эсциталопрама
BR0206164A (pt) 2001-07-31 2003-10-28 Lundbeck & Co As H Partìculas cristalinas de oxalato de escitalopram, método para a produção de partìculas cristalinas de oxalato de escitalopram, e, forma de dosagem unitária sólida
WO2004004721A1 (en) * 2002-07-08 2004-01-15 University Of Florida Use of ssri inhibitors to prevent or ameliorate trauma-related psychological disorders
UA80170C2 (en) * 2002-12-23 2007-08-27 Lundbeck & Co As H Escitalopram hydrobromide
US20050137255A1 (en) * 2002-12-23 2005-06-23 H. Lundbeck A/S Crystalline escitalopram hydrobromide and methods for preparing the same
US20050154052A1 (en) * 2003-03-24 2005-07-14 Hetero Drugs Limited Novel crystalline forms of (s)-citalopram oxalate
US20090093461A1 (en) * 2003-07-02 2009-04-09 Astrazeneca Ab Methods of Treating Anxiety and Mood Disorders
US7884096B2 (en) * 2003-12-02 2011-02-08 Pharmaneuroboost N.V. Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
CA2547639A1 (en) * 2003-12-02 2005-06-16 B&B Beheer Nv Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
US7855195B2 (en) * 2003-12-02 2010-12-21 Pharmaneuroboost N.V. Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP1954257A4 (en) 2005-10-14 2009-05-20 Lundbeck & Co As H METHOD FOR TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM WITH A LOW-DOSED COMBINATION OF ESCITALOPRAM AND BUPROPION
US20070134322A1 (en) * 2005-12-14 2007-06-14 Forest Laboratories, Inc. Modified and pulsatile release pharmaceutical formulations of escitalopram
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1143702A (https=) 1965-03-18
GB1526331A (en) 1976-01-14 1978-09-27 Kefalas As Phthalanes
US4439545A (en) 1981-11-19 1984-03-27 Societe D "Expansion Scientifique "Expansia" Acrylic copolymers of N-acryloylpolymethyleneimines or N-acryloyldialkylamides, N,N'-acryloyldiaminoalcanes and N-acryloylaminoacids (or esters) their preparation and use as cation exchangers
GB8419963D0 (en) 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method
GB8607313D0 (en) * 1986-03-25 1986-04-30 Ici Plc Pharmaceutical compositions
GB8814057D0 (en) 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
US4902710A (en) 1988-12-14 1990-02-20 Eli Lilly And Company Serotonin and norepinephrine uptake inhibitors
US5114976A (en) 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US4962128A (en) 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
DK213290D0 (da) 1990-09-06 1990-09-06 Lundbeck & Co As H Treatment of cerebrovascular disorders
US5296507A (en) * 1990-09-06 1994-03-22 H.Lundbeck A/S Treatment of cerbrovascular disorders
US5708035A (en) 1991-02-04 1998-01-13 Sepracor Inc. Methods of use and compositions of R(-) fluoxetine
WO1992018005A1 (en) 1991-04-16 1992-10-29 National Institutes Of Health Method of treating trichotillomania and onychophagia
ATE244563T1 (de) 1991-11-15 2003-07-15 Sepracor Inc Verwendung von reinem fluoxetin-s(+)-isomer für die herstellung eines medikements gegen migräne
EP0714663A3 (en) * 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
US5627196A (en) * 1995-01-17 1997-05-06 Eli Lilly And Company Compounds having effects on serotonin-related systems
WO1996024353A1 (en) * 1995-02-10 1996-08-15 Eli Lilly And Company Methods of treating or preventing psychiatric disorders
US5554383A (en) 1995-04-06 1996-09-10 Trustees Of Tufts College Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
SE9501567D0 (sv) 1995-04-27 1995-04-27 Astra Ab A new combination
ATE192042T1 (de) 1995-08-16 2000-05-15 Lilly Co Eli Potenzierung von serotonin-wirkstoffresponz
US5846982A (en) * 1996-06-14 1998-12-08 Eli Lilly And Company Inhibition of serotonin reuptake
US5912256A (en) * 1996-06-20 1999-06-15 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5747494A (en) * 1996-06-28 1998-05-05 U C B S.A. Pharmaceutical compositions for the treatment of depressive disorders
US5958429A (en) 1996-08-16 1999-09-28 Eli Lilly And Company Potentiation of serotonin response
ZA977967B (en) 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
US5776969A (en) * 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders
US6069177A (en) 1997-07-08 2000-05-30 The Hong Kong University Of Science And Technology 3-Hydroxy-propanamine derived neuronal reuptake inhibitors
SE9703375D0 (sv) 1997-09-18 1997-09-18 Astra Ab A new combination
SE9703379D0 (sv) * 1997-09-18 1997-09-18 Astra Ab New compounds
EP1042310B1 (en) * 1997-11-11 2002-07-31 H. Lundbeck A/S Method for the preparation of citalopram
ATE228119T1 (de) * 1998-04-15 2002-12-15 Pfizer Prod Inc Heterocyclische carboxamide
EP1100501A4 (en) * 1998-06-30 2002-12-04 Lilly Co Eli PYRROLIDINE AND PYRROLIDINE DERIVATIVES INFLUENTING THE SYSTEMS ASSOCIATED WITH SEROTONIN
AU771252B2 (en) 1998-07-13 2004-03-18 Nps Pharmaceuticals, Inc. Methods and compounds for treating depression and other disorders
US6579899B1 (en) 1998-07-16 2003-06-17 Massachusetts Institute Of Technology Composition for treatment of stress
JP2002520353A (ja) 1998-07-16 2002-07-09 マサチューセッツ インスティテュート オブ テクノロジー ストレスの処置のための組成物
US6150376A (en) * 1998-08-05 2000-11-21 Georgetown University Bi- and tri-cyclic aza compounds and their uses
SE9803157D0 (sv) 1998-09-16 1998-09-16 Astra Ab A new composition
SE9803158D0 (sv) * 1998-09-16 1998-09-16 Astra Ab A new composition
CA2291134C (en) * 1998-10-20 2006-05-23 H. Lundbeck A/S Method for the preparation of citalopram
AR021509A1 (es) * 1998-12-08 2002-07-24 Lundbeck & Co As H Derivados de benzofurano, su preparacion y uso
AU759716B2 (en) * 1999-04-14 2003-04-17 H. Lundbeck A/S Method for the preparation of citalopram
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
US6333357B1 (en) 1999-11-05 2001-12-25 Be Able, Llc Behavior chemotherapy
UA77650C2 (en) 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
GB2357762B (en) * 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
WO2001080845A2 (en) 2000-04-24 2001-11-01 Aryx Therapeutics (2-aminoethyl) oxime derivatives for the treatment of depression
JP2002361405A (ja) * 2000-09-25 2002-12-18 Showa Denko Kk 熱交換器の製造方法
EA200301195A1 (ru) * 2001-05-01 2004-04-29 Х. Лундбекк А/С Применение энантиомерно чистого эсциталопрама

Also Published As

Publication number Publication date
TR200402276T2 (tr) 2005-01-24
HK1048069B (zh) 2005-12-16
HUP0201791A3 (en) 2005-02-28
EP1440691A3 (en) 2004-08-25
BG110467A (en) 2010-01-29
EP1440690A3 (en) 2004-08-18
AU2005202686A1 (en) 2005-07-14
MY143278A (en) 2011-04-15
CL2008003939A1 (es) 2009-06-05
CA2373757A1 (en) 2001-01-18
IL170194A (en) 2010-05-31
IS6137A (is) 2001-10-30
CN1360501A (zh) 2002-07-24
CA2687392A1 (en) 2001-01-18
WO2001003694A1 (en) 2001-01-18
MXPA01011626A (es) 2002-06-04
CY1105806T1 (el) 2011-02-02
CL2008003941A1 (es) 2009-05-22
NO20100335L (no) 2002-01-07
US20050101665A1 (en) 2005-05-12
AU2005202684B2 (en) 2009-01-15
NO20020062D0 (no) 2002-01-07
ATE339955T1 (de) 2006-10-15
DE60030861D1 (de) 2006-11-02
AU2005202684A1 (en) 2005-07-14
EA200200137A1 (ru) 2002-06-27
BR0011578A (pt) 2002-03-26
AU5806100A (en) 2001-01-30
CA2687396A1 (en) 2001-01-18
TWI232101B (en) 2005-05-11
IL146131A0 (en) 2002-07-25
NO20100334L (no) 2002-01-07
CA2373757C (en) 2010-01-05
NO329021B1 (no) 2010-07-26
NO20020062L (no) 2002-01-07
SI1200081T1 (sl) 2007-02-28
BG106279A (bg) 2002-08-30
SK82002A3 (en) 2002-07-02
AU782514B2 (en) 2005-08-04
EP1440690A2 (en) 2004-07-28
ES2272298T3 (es) 2007-05-01
EP1200081A1 (en) 2002-05-02
BG110466A (en) 2010-01-29
HRP20010820A2 (en) 2003-08-31
DE60030861T2 (de) 2007-05-03
PT1200081E (pt) 2007-01-31
MEP2508A (xx) 2010-02-10
PL352030A1 (en) 2003-07-28
EP1200081B1 (en) 2006-09-20
CO5190674A1 (es) 2002-08-29
US20070276035A1 (en) 2007-11-29
AU2005202686B2 (en) 2009-01-15
EP1440691A2 (en) 2004-07-28
EP1440689A3 (en) 2004-08-25
ME00032B (me) 2010-02-10
ZA200108856B (en) 2002-12-24
UA77645C2 (en) 2007-01-15
CA2687394A1 (en) 2001-01-18
US20040029956A1 (en) 2004-02-12
AU2008264182A1 (en) 2009-01-29
YU78701A (sh) 2004-03-12
AU2008264188A1 (en) 2009-05-07
US20040029958A1 (en) 2004-02-12
JP4773011B2 (ja) 2011-09-14
US20020086899A1 (en) 2002-07-04
IL170192A (en) 2010-04-29
EP1440689A2 (en) 2004-07-28
US7265151B2 (en) 2007-09-04
KR100604176B1 (ko) 2006-07-25
TR200402277T2 (tr) 2005-01-24
US20040029957A1 (en) 2004-02-12
CZ200270A3 (cs) 2002-04-17
AR021155A1 (es) 2002-06-12
US7271194B2 (en) 2007-09-18
CN1198610C (zh) 2005-04-27
US6960613B2 (en) 2005-11-01
IL146131A (en) 2007-02-11
BG110468A (en) 2010-01-29
DK1200081T3 (da) 2006-12-27
HK1048069A1 (en) 2003-03-21
KR20020015346A (ko) 2002-02-27
IL170193A (en) 2010-04-29
NO20100333L (no) 2002-01-07
AU2005202685B2 (en) 2009-01-15
AU2005202685A1 (en) 2005-07-14
CL2008003938A1 (es) 2009-05-22
TR200200014T2 (tr) 2002-05-21
HUP0201791A2 (en) 2002-10-28
JP2003504332A (ja) 2003-02-04
EA006555B1 (ru) 2006-02-24

Similar Documents

Publication Publication Date Title
TR200402275T2 (tr) Nörotik düzensizliklerin tedavisi
CY1105082T1 (el) Χρηση της φλιβανσepινης στην αγωγη διαταραχων της σεξουαλικης επιθυμιας
CA2436799A1 (en) Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders
FI956014A0 (fi) Nona- ja dekapeptidien käyttö lääkkeen valmistamiseksi AIDS-sairauden hoitoon
AR034213A1 (es) Composiciones de medicamentos sobre la base de agentes anticolinergicos e inhibidores de pde-iv
CY1109238T1 (el) Δισκιο περιεχον σετιριζινη και ψευδοεφεδρινη
PT1176963E (pt) Utilizacao de ligandos do receptor d3 da dopamina no fabrico de medicamentos para o tratamento de disturbios da funcao renal
CY1109361T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
BR0210650A (pt) Tablete, e, uso do mesmo
IT1305313B1 (it) 3,4 - diidro- 6- benzil-4-oxopirimidine sostituite e relativo processodi produzione e impiego nella terapia delle infezioni da hiv-1.
SE0102147D0 (sv) New methods
BR0012291A (pt) Fenoxifluorpirimidinas
DK1643999T3 (da) Pyridoxamin til anvendelse ved behandlingen af diabetisk nefropati ved type 2-diabetes
ATE525112T1 (de) Kombination aus flupirtin und tramadaol
PT1030667E (pt) Utilizacao de mirtazapina para o fabrico de um medicamento para o tratamento de apenas do sono
AR023597A1 (es) Utilizacion del saredutant y de sus sales farmaceuticamente aceptables para la preparacion de medicamentos utiles en el tratamiento o la prevencion delconjunto de los trastornos del humor, de los trastornos de adaptacion o de los trastornos mixtos ansiedad-depresion
EE200300129A (et) Distamütsiini alfa-halogenoakrüloüülderivaadi kasutamine
BR0116653A (pt) Medicamento contendo uma poliamina como substância ativa
MXPA04001912A (es) Aminobenzofenonas novedosas.
HRP20080597T3 (en) Cancer combination therapy comprising azd2171 and zd1839
DE50111407D1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
DE50005714D1 (de) Pharmazeutische zusammensetzung, umfassend eukalyptus- und orangenöl
BR0015938A (pt) Uso de antagonistas beta-adrenoceptores para a fabricação de um medicamento para o tratamento de desordens da retina externa
BR0214060A (pt) Uso de monoidroxicarbamazepina em distúrbio afetivo e de atenção e dor neuropática
DE60216142D1 (de) Tropan-derivate mit dopamin-wiederaufnahme-hemmer-wirkung für die behandlung von ischämischen erkrankungen